Nachrichten zur GSK PLC Aktie

GSK (GSK) Outpaces Stock Market Gains: What You Should Know

GSK (GSK) closed the most recent trading day at $38.32, moving +1.62% from the previous trading session....…

Can Pfizer Beat GSK and Moderna in This $10 Billion Market?

Theres such a big need in preventing RSV that multiple companies should be big winners....…

Adaptimmune (ADAP) Up 7%, Gets T-Cell Programs Rights From GSK

Adaptimmune Therapeutics (ADAP) enters into a transition deal with GSK to regain rights to its proprietary T-cell therapy programs. Shares…

GSK growth outlook being overlooked due to Zantac concerns

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...…

Adaptimmune to regain rights to cancer drug programs from GSK

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Adaptimmune Therapeutics PLC: Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune

- Adaptimmune plans to be IND-ready in 2023 with a PRAME targeted TCR T-cell therapy -- Adaptimmune and GSK will…

GSK (GSK) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, GSK (GSK) closed at $37.87, marking a -0.34% move from the previous day....…

GSK ordered by UK court to pay more royalties to AstraZeneca on Zejula sales - report

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

UK court orders GSK to pay AstraZeneca royalties on total sales of Zejula

...(Reuters) - A UK court on Wednesday ordered GSKs Tesaro to pay......…

Amid Backlash, Volkswagen, GSK, Total Develop Own Carbon Offsets

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...…

GSK (GSK) Gains As Market Dips: What You Should Know

In the latest trading session, GSK (GSK) closed at $36.55, marking a +1.67% move from the previous day....…

GSK: Will vaccines do the trick? This leading bank has its say

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 6-K GSK PLC For: Apr 03

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Liquidia and GSK Restructure License to PRINT Technology for Inhaled Applications

MORRISVILLE, N.C., April 03, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced today…

Scynexis (SCYX) Inks Antifungal Drug Deal With GSK

Scynexis (SCYX) enters an exclusive license agreement with GSK to commercialize Brexafemme (ibrexafungerp), an antifungal tablet. GSK will also continue…

UPDATE 2-GSK licenses companies to make cheap copies of HIV prevention drug

..., March 30 (Reuters) - British drugmaker GSK has signed deals......…

Scynexis +55% nach Mega-Deal – Aktie noch ein Kauf?

Die Aktie von Scynexis (WKN: A2P9T4) beendet endlich ihre Durststrecke: GlaxoSmithKline kauft die Rechte am zugelassenen Vertriebsprodukt Brexafemme und zahlt…

GSK sees $500 million peak sales for yeast infection pill licensed from Scynexis

...By Maggie Fick LONDON (Reuters) - British drugmaker GSK sees peak......…

Scynexis Shares Jump 60% After Licensing Deal With GSK

Scynexis Shares Jump 60% After Licensing Deal With GSK...…

Anti-Fungal Maker Scynexis Stock Soars on GSK Deal

Under the terms of the deal, GSK (GSK) will pay $90 million up front, plus up to $503 million more…

SCYNEXIS jumps 92% on licensing deal with GSK for anti-fungal agent

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

GSK, SCYNEXIS Ink Exclusive Licence Agreement For Brexafemme

LONDON (dpa-AFX) - GSK plc (GSK, GSK.L) and SCYNEXIS, Inc. (SCYX) announced Thursday they have entered into an exclusive licence…

BRIEF-GSK And Scynexis Announce An Exclusive Agreement To Commercialise & Develop Brexafemme To Treat Fungal Infection

...March 30 (Reuters) - GSK plc: * GSK - GSK AND SCYNEXIS ANNOUNCE......…

GSK agrees HIV deal that gives lower income nations access to drug

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...…

GSK licenses companies to make cheap copies of HIV prevention drug

...By Maggie Fick LONDON (Reuters) - British drugmaker GSK has......…

J&J backs out of RSV vaccine race with rivals Pfizer and GSK

J&J lagged behind rival drugmakers Pfizer and GSK, both of which made major strides toward U.S. approval of their RSV…

Form 6-K GSK PLC For: Mar 28

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

GSK says RUBY dostarlimab phase 3 trial shows positive results

Um den gesamten Artikel unter morningstar.co.uk zu lesen, klicken Sie bitte auf die Überschrift...…

GSK Jemperli cuts risk of death in uterus cancer patients subset by 72% but lower overall in trial

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

GSK Announces Positive Results From Phase III Trial Of Jemperli Combination In Endometrial Cancer

LONDON (dpa-AFX) - GSK PLC (GSK.L, GSK) announced positive results from Part 1 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial investigating…

BRIEF-Gsk Says Jemperli Regulatory Submissions Planned For First Half Of 2023

...March 28 (Reuters) - GSK plc: * POSITIVE PHASE III RUBY RESULTS......…

GSK (GSK) Outpaces Stock Market Gains: What You Should Know

GSK (GSK) closed at $35.04 in the latest trading session, marking a +1.92% move from the prior day....…

AnaptysBio- and GSK-partnered immuno-oncology agent Jemperli (dostarlimab-gxly) plus chemotherapy demonstrates statistically significant and clinically meaningful improvement in progression-free survival for the treatment of primary advanced or recur

SAN DIEGO, March 27, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on…

dpa-AFX ProFeed